International Journal of Hematology

, Volume 92, Issue 5, pp 762–764

Interferon-α and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients

  • Kenji Ishitsuka
  • Hiroo Katsuya
  • Tomona Toyota
  • Masanao Ishizu
  • Naoko Kunami
  • Mana Fujita
  • Hidenori Sasaki
  • Yasushi Takamatsu
  • Masanobu Uchiyama
  • Haruo Fujikane
  • Kentaro Ogata
  • Shuuji Hara
  • Kazuo Tamura
Case Report

DOI: 10.1007/s12185-010-0717-3

Cite this article as:
Ishitsuka, K., Katsuya, H., Toyota, T. et al. Int J Hematol (2010) 92: 762. doi:10.1007/s12185-010-0717-3

Abstract

Combination therapy with interferon-α and zidovudine (IFN/AZT) has been regarded as standard care for acute and indolent (i.e., chronic and smouldering) ATL based on reports involving a limited number of patients. This treatment approach has not been evaluated in Japan, a major endemic area of this disease in the world. This is the first Japanese report of IFN/AZT for ATL. It is impossible to draw any definitive conclusion from this small study; however, IFN/AZT showed clear anti-ATL effects for refractory/relapsed ATL patients. This report would contribute for developing future ATL treatment in Japan.

Keywords

ATLInterferonZidovudine

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Kenji Ishitsuka
    • 1
  • Hiroo Katsuya
    • 1
  • Tomona Toyota
    • 1
  • Masanao Ishizu
    • 1
  • Naoko Kunami
    • 1
  • Mana Fujita
    • 1
  • Hidenori Sasaki
    • 1
  • Yasushi Takamatsu
    • 1
  • Masanobu Uchiyama
    • 2
  • Haruo Fujikane
    • 2
  • Kentaro Ogata
    • 3
  • Shuuji Hara
    • 3
  • Kazuo Tamura
    • 1
  1. 1.Division of Medical Oncology, Hematology and Infectious DiseaseFukuoka UniversityFukuokaJapan
  2. 2.Department of PharmacyFukuoka University HospitalFukuokaJapan
  3. 3.Faculty of Pharmaceutical SciencesFukuoka UniversityFukuokaJapan